Development of an Intranasal Proteosome Influenza Vaccine

Summary

A study to compare multiple dosage regimes of a protesomal intranasal vaccine.

Timeline

Start

2002-01

Primary completion

2004-01

Completion

2004-01

Publications

• Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection. PLoS One. 2016 Dec 22;11(12):e0163089. doi: 10.1371/journal.pone.0163089. eCollection 2016.

Drugs

Indications